DVDiego Velasco-Rodríguez

Diego Velasco-Rodríguez

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Diego Velasco-Rodríguez has a total of 121 co-authors. Here are the top co-authors by number of shared publications:

  • Jesús Villarrubia

    University Hospital Ramón y Cajal, Madrid, Spain

    9 shared publications
  • Juan Manuel Alonso-Dominguez

    Hospital Universitario Fundación Jiménez Díaz Madrid Spain

    8 shared publications
  • Inés Martínez-Alfonzo

    Department of Hematology, Hospital Universitario Fundación Jiménez Díaz, IIS-FJD, Madrid, Spain

    4 shared publications
  • Nuria Revilla

    Department of Hematology, Hospital Universitario Fundación Jiménez Díaz, IIS-FJD, Madrid, Spain

    4 shared publications
  • Pilar Llamas-Sillero

    Department of Hematology, Hospital Universitario Fundación Jiménez Díaz, IIS-FJD, Madrid, Spain; Department of Hematology, Hospital Universitario Rey Juan Carlos, Móstoles, Madrid, Spain; Department of Hematology, Hospital Universitario General de Villalba, Collado Villalba, Madrid, Spain; Department of Hematology, Hospital Universitario Infanta Elena, Valdemoro, Madrid, Spain

    4 shared publications
  • Ana Jiménez-Martín

    Department of Hematology, Hospital Universitario Ramón y Cajal, Madrid, Spain

    3 shared publications

Latest Publications

  • Open Access

    Multicenter Interlaboratory Study of Thrombin Generation Assay in Healthy Adults Using the ST Genesia Analyzer With the STG‐ThromboScreen Reagent (With and Without Thrombomodulin)

    by Diego Velasco‐Rodríguez, María Marcos‐Jubilar, Inés Martínez‐Alfonzo, Laura Martos, Carlos Aguilar, Noelia Vilalta, Dolors Llobet, Ana Marco‐Rico, David Aragoneses, Pascual Marco, et al.

    Introduction: Fully automated thrombin generation (TG) assays facilitate the transition from research to clinical application. We conducted a multicenter inter‐laboratory study using the ST Genesia analyzer to evaluate assay performance and establish reference intervals in healthy adults from Spain and Portugal. Methods: In this multicenter study, plasma samples from healthy adult volunteers were analyzed across 12 laboratories following a harmonized protocol. TG was measured using the STG‐ThromboScreen reagent in the presence and absence of thrombomodulin (TM). Analytical performance and reference intervals were assessed. Results: Within‐run and intra‐day precision were excellent (coefficient of variation < 10%) for all TG parameters except velocity index. Normalization reduced interlaboratory variability for amplitude‐based parameters such as endogenous thrombin potential (ETP) and peak height, whereas its effect was less pronounced for velocity index. Satisfactory interlaboratory performance (| z | ≤ 2) was achieved in 96%–98% of results, and normalized parameters showed minimal bias across centers. In 252 healthy adults, median normalized values were: ETP 131% (IQR 118–142), peak height 116% (IQR 104–127), lag time 2.6 min (IQR 2.3–2.8), and time‐to‐peak 5.5 min (IQR 5.0–5.9). Median ETP inhibition in the presence of TM was 47.2% (IQR 35.1–61.8). Age had a modest influence on TG parameters, whereas sex differences were observed. Conclusions: This multicenter interlaboratory study in the Iberian Peninsula demonstrates high reproducibility of TG measurement using the ST Genesia platform with the STG‐ThromboScreen reagent. These findings support its use for standardized TG assessment and provide reference intervals for clinical and research settings.

  • APTTO: a clot waveform analysis–based algorithm for diagnostic triage of prolonged activated partial thromboplastin time

    by Diego Velasco-Rodríguez, Nuria Revilla, Ignacio Mahíllo-Fernández, Elena Vega-Romero, Jorge Ortega-Carriedo, Rosa Vidal Laso, Inés Martínez-Alfonzo, Gabriela Salvatierra, María Yuste, Pilar Beltrán, et al.

  • Open Access

    Development of PREVEMM: A Venous Thromboembolism Risk Score for Newly Diagnosed Multiple Myeloma Patients

    by Inés Martínez-Alfonzo, Diego Velasco-Rodríguez, Pablo Mínguez-Paniagua, Ignacio Mahillo-Fernández, Laura Fernández-Cuezva, Alberto Velasco-Valdazo, Rosa Vidal-Laso, Cristina Fernández Maqueda, Sara Martín-Herrero, Nuria Revilla, et al.

  • Significant attenuation of fully automated thrombin generation in newly diagnosed multiple myeloma patients after induction therapy

    by Diego Velasco-Rodríguez, Inés Martínez-Alfonzo, Alberto Eterio Velasco-Valdazo, Amalia Domingo-González, Nuria Revilla, Ignacio Mahíllo-Fernández, Elham Askari, María Jesús Blanchard, Rosa Vidal Laso, Laura Fernández-Cuezva, et al.

    Nearly 10% of newly diagnosed multiple myeloma (NDMM) patients develop a venous thromboembolism (VTE) episode during their disease course, despite current thromboprophylaxis strategies. Changes in hypercoagulability in these patients after treatment have been analyzed using the thrombin generation (TG) assay, the results being discrepant, probably due to the use of semi-automated techniques. This study aims to assess changes in TG measured by a fully automated analyzer. This prospective and multicentric study included NDMM patients from 8 centers (December 2018–September 2023). Fully automated TG was measured at baseline and after 1 and 4 cycles of treatment with ST Genesia® analyzer. Among 100 NDMM patients, a significant decrease was observed in velocity index (after 1 cycle) and peak height (after 4 cycles) and alongside increased sensitivity to thrombomodulin (after 4 cycles), indicating a reduction in hypercoagulability post-treatment. No differences in TG were observed according to the depth of response after 4 cycles. Patients on daratumumab-containing regimens experienced a transient increase in TG after cycle 1, whereas those on proteasome inhibitors (PI)-containing regimens showed a significant reduction in peak height and velocity index after 4 cycles. The development of a VTE event was associated with increased mortality, but there was no association between VTE development and TG results at baseline. Hypercoagulability decreases with anti-myeloma treatment, especially in those receiving PI-containing regimens. These changes in TG are not related to the depth of response to treatment. Graphical abstract

  • Open Access

    PB0990 Changes in Thrombin Generation Parameters in Newly Diagnosed Multiple Myeloma Patients in Response to Anti-Myeloma Therapy

    by D. Velasco-Rodríguez, I. Martínez-Alfonzo, A. Velasco-Valdazo, N. Revilla, R. Vidal-Laso, J. Alonso-Dominguez, E. Askari, A. Domingo-González, N. Castro-Quismondo, J. Serrano-López, et al.

  • Enhanced thrombin generation detected with ST-Genesia analyzer in patients with newly diagnosed multiple myeloma

    by Diego Velasco-Rodríguez, Inés Martínez-Alfonzo, Alberto Eterio Velasco-Valdazo, Nuria Revilla, Ignacio Mahíllo-Fernández, Elham Askari, Nerea Castro-Quismondo, Rosa Vidal Laso, Amalia Domingo-González, Juana Serrano-López, et al.

    The issue of how to identify newly diagnosed multiple myeloma (NDMM) patients requiring thromboprophylaxis remains unsolved. Several changes in thrombin generation (TG)-derived parameters have been described in multiple myeloma (MM) patients recently. Assessment of prothrombotic risk with a fully automated TG analyzer could reduce interlaboratory variability. Our objective was to determine whether ST-Genesia® could reveal a hypercoagulable state in NDMM compared to healthy controls. We conducted a multicenter observational study of NDMM requiring initial treatment to compare TG parameters obtained with ST-Genesia® analyzer and ST-ThromboScreen® reagent with a control group. Clinical data were obtained from medical records and blood samples were collected before initial anti-myeloma therapy. A thrombophilia panel was performed in all patients. Compared to age- and sex-matched controls (n = 83), NDMM patients (n = 83) had significantly higher peak height, higher velocity index, shorter time-to-peak and lower percentage of endogenous thrombin potential (ETP) inhibition after adding thrombomodulin (TM) (ETP%inh). NDMM on prophylactic low molecular weight heparin (LMWH) showed reduced both peak height and velocity index compared to NDMM who had not yet started VTE prophylaxis, similar to that of controls. Moreover, partial correction of ETP%inh was observed in MM patients on LMWH. The presence of a thrombophilia did not modify the TG phenotype. Untreated NDMM patients showed an enhanced TG, regardless of their thrombophilia status. They generate a higher peak of thrombin, take less time to produce it, and exhibit resistance to TM inhibition. Our findings suggest that standard prophylactic dose of LMWH may reduce TG at levels of healthy controls.


  • Open Access

    Cut-Off Values of Hematologic Parameters to Predict the Number of Alpha Genes Deleted in Subjects with Deletional Alpha Thalassemia

    by Diego Velasco-Rodríguez, Carlos Blas, Juan-Manuel Alonso-Domínguez, Gala Vega, Carlos Soto, Aránzazu García-Raso, Pilar Llamas-Sillero

    Most α-thalassemia cases are caused by deletions of the structural α-globin genes. The degree of microcytosis and hypochromia has been correlated with the number of affected α-globin genes, suggesting a promising role of hematologic parameters as predictive diagnostic tools. However, cut-off points for these parameters to discriminate between the different subtypes of α-thalassemia are yet to be clearly defined. Six hematologic parameters (RBC, Hb, MCV, MCH, MCHC and RDW) were evaluated in 129 cases of deletional α-thalassemia (56 heterozygous α+ thalassemia, 36 homozygous α+ thalassemia, 29 heterozygous α0 thalassemia and 8 cases of Hb H disease). A good correlation between the number of deleted alpha genes and MCV (r = −0.672, p < 0.001), MCH (r = −0.788, p < 0.001) and RDW (r = 0.633, p < 0.001) was observed. The presence of an α0 allele should be discarded in individuals with microcytosis without iron deficiency and normal values of Hb A2 and Hb F with MCH < 23.40 pg. Furthermore, MCH < 21.90 pg and/or MCV < 70.80 fL are strongly suggestive of the presence of one α0 allele. Finally, an accurate presumptive diagnosis of Hb H disease can be made if both RDW ≥ 20% and MCH < 19 pg are seen.


  • Bullous dermatosis at distant sites in patients treated with heparin

    by María Castellanos-González, Diego Velasco-Rodríguez, Ana Belén Mancebo Plaza


  • Open Access

    Type B Niemann–Pick disease

    by Jesús Villarrubia, Diego Velasco‐Rodríguez, Miguel Piris‐Villaespesa, María Caro, Gala Méndez, Ana Vallés


  • Cryofibrinogenaemia in a patient with multiple myeloma and necrotizing vasculitis

    by Diego Velasco‐Rodríguez, José Á. Hernández‐Rivas, Eva Chavarría, Teresa Navío, Jesús Villarrubia